Mostrar el registro sencillo del ítem

dc.contributor.authorMonteagudo, Paula L.
dc.contributor.authorLacasta, Anna
dc.contributor.authorLópez, Elisabeth
dc.contributor.authorBosch, Laia
dc.contributor.authorCollado, Javier
dc.contributor.authorPina-Pedrero, Sonia
dc.contributor.authorCorrea-Fiz, Florencia
dc.contributor.authorAccensi, Francesc
dc.contributor.authorNavas, María Jesús
dc.contributor.authorVidal, Enric
dc.contributor.authorBustos, María J.
dc.contributor.authorRodriguez Martinez, Javier M 
dc.contributor.authorGallei, Andreas
dc.contributor.authorNikolin, Veljko
dc.contributor.authorSalas, María L.
dc.contributor.authorRodríguez, Fernando 
dc.date.accessioned2019-02-07T14:42:07Z
dc.date.available2019-02-07T14:42:07Z
dc.date.issued2017-10
dc.identifier.citationJ Virol. 2017 Oct 13;91(21). pii: e01058-17es_ES
dc.identifier.issn0022-538Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7146
dc.description.abstractAfrican swine fever is a highly contagious viral disease of mandatory declaration to the World Organization for Animal Health (OIE). The lack of available vaccines makes its control difficult; thus, African swine fever virus (ASFV) represents a major threat to the swine industry. Inactivated vaccines do not confer solid protection against ASFV. Conversely, live attenuated viruses (LAV), either naturally isolated or obtained by genetic manipulation, have demonstrated reliable protection against homologous ASFV strains, although little or no protection has been demonstrated against heterologous viruses. Safety concerns are a major issue for the use of ASFV attenuated vaccine candidates and have hampered their implementation in the field so far. While trying to develop safer and efficient ASFV vaccines, we found that the deletion of the viral CD2v (EP402R) gene highly attenuated the virulent BA71 strain in vivo Inoculation of pigs with the deletion mutant virus BA71ΔCD2 conferred protection not only against lethal challenge with the parental BA71 but also against the heterologous E75 (both genotype I strains). The protection induced was dose dependent, and the cross-protection observed in vivo correlated with the ability of BA71ΔCD2 to induce specific CD8+ T cells capable of recognizing both BA71 and E75 viruses in vitro Interestingly, 100% of the pigs immunized with BA71ΔCD2 also survived lethal challenge with Georgia 2007/1, the genotype II strain of ASFV currently circulating in continental Europe. These results open new avenues to design ASFV cross-protective vaccines, essential to fight ASFV in areas where the virus is endemic and where multiple viruses are circulating.IMPORTANCE African swine fever virus (ASFV) remains enzootic in most countries of Sub-Saharan Africa, today representing a major threat for the development of their swine industry. The uncontrolled presence of ASFV has favored its periodic exportation to other countries, the last event being in Georgia in 2007. Since then, ASFV has spread toward neighboring countries, reaching the European Union's east border in 2014. The lack of available vaccines against ASFV makes its control difficult; so far, only live attenuated viruses have demonstrated solid protection against homologous experimental challenges, but they have failed at inducing solid cross-protective immunity against heterologous viruses. Here we describe a new LAV candidate with unique cross-protective abilities: BA71ΔCD2. Inoculation of BA71ΔCD2 protected pigs not only against experimental challenge with BA71, the virulent parental strain, but also against heterologous viruses, including Georgia 2007/1, the genotype II strain of ASFV currently circulating in Eastern Europe.es_ES
dc.description.sponsorshipThis work has been supported by Spanish government grants from the Ministerio de Economía y Competitividad de España (MINECO), AGL2013-48998-C2-1-R, AGL2013-48998-C2-2-R, and AGL2016-78160-C2-1-R, and by Boehringer Ingelheim Veterinary Research Center GmbH & Co. KG, Hannover, Germany.es_ES
dc.language.isoenges_ES
dc.publisherAmerican Society for Microbiology (ASM) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectAfrican swine fever viruses_ES
dc.subjectCD8 T cellses_ES
dc.subjectCross-protectiones_ES
dc.subjectLive attenuated viruses_ES
dc.subjectVaccinees_ES
dc.subject.meshAfrican Swine Fever es_ES
dc.subject.meshAfrican Swine Fever Virus es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshAntibodies, Viral es_ES
dc.subject.meshCells, Cultured es_ES
dc.subject.meshImmunization es_ES
dc.subject.meshMacrophages es_ES
dc.subject.meshSwine es_ES
dc.subject.meshVaccines, Attenuated es_ES
dc.subject.meshViral Proteins es_ES
dc.subject.meshViral Vaccines es_ES
dc.titleBA71ΔCD2: a New Recombinant Live Attenuated African Swine Fever Virus with Cross-Protective Capabilitieses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID28814514es_ES
dc.format.volume91es_ES
dc.format.number21es_ES
dc.identifier.doi10.1128/JVI.01058-17es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1098-5514es_ES
dc.relation.publisherversionhttps://www.doi.org/10.1128/JVI.01058-17es_ES
dc.identifier.journalJournal of Virologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional